Physician profile
John Gonzalez
NPI 1700857927
$27,680.11
in general payments reported to CMS, 2019-2025
40 companies · $446 in 2025
The $446 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $312 · 2020: $407 · 2021: $550 · 2022: $1,067 · 2023: $18K · 2024: $6,905 · 2025: $446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $16K · Travel and Lodging: $4,561 · Food and Beverage: $3,924 · Consulting Fee: $1,350 · Gift: $8.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $15,500.00 |
| Travel and Lodging | $4,561.46 |
| Food and Beverage | $3,924.02 |
| Consulting Fee | $1,350.00 |
| Gift | $8.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $22,359.73 | 2020-2025 | Davinci Xi, Da Vinci Surgical System |
| Ambu INC. | $1,350.00 | 2024 | |
| Medtronic, INC. | $781.95 | 2021-2025 | Signia, Ligasure, Sonicision |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $562.29 | 2019-2023 | Xifaxan |
| Lexington Medical, INC. | $520.45 | 2021-2025 | Aeon Endostapler & Echelon Flex Powered Stapler |
| Lilly USA, LLC | $226.58 | 2022-2025 | Zepbound, Mounjaro |
| Daiichi Sankyo INC. | $220.40 | 2020-2023 | Injectafer |
| Novo Nordisk INC | $218.37 | 2019-2024 | Wegovy |
| Endo Pharmaceuticals INC. | $145.13 | 2019-2021 | |
| Covidien Lp | $139.08 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $134.66 | 2024 | Voquezna |
| Vertex Pharmaceuticals Incorporated | $114.94 | 2024-2025 | |
| Philips North America LLC | $100.21 | 2020 | |
| Pacira Pharmaceuticals Incorporated | $91.54 | 2021-2025 | Exparel |
| Takeda Pharmaceuticals U.S.A., INC. | $91.26 | 2021-2023 | Gattex |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.